Natixis Mirati Therapeutics, Inc. Transaction History

Natixis

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $9.06 Million - $13.5 Million	215,731 New	215,731 $12.7 Million
Q2 2023 Aug 11, 2023	SELL	$36.13 - $49.49 $1.02 Million - $1.4 Million	-28,209 Reduced 88.96%	3,500 $126,000
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $1.16 Million - $1.72 Million	31,709 New	31,709 $1.18 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $1.31 Million - $3.14 Million	31,800 Added 363.43%	40,550 $1.84 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $520,625 - $758,625	8,750 New	8,750 $611,000

Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $1.02 Million - $2.03 Million	-13,450 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.78 Million - $2.56 Million	13,450 New	13,450 $1.97 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.